<SEC-DOCUMENT>0001193125-12-056661.txt : 20120213
<SEC-HEADER>0001193125-12-056661.hdr.sgml : 20120213
<ACCEPTANCE-DATETIME>20120213171609
ACCESSION NUMBER:		0001193125-12-056661
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120213
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120213
DATE AS OF CHANGE:		20120213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		12600296

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d300377d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 OR 15(d) of The </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act Of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): February&nbsp;13, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>BRISTOL-MYERS SQUIBB COMPANY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-1136</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22-079-0350</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>345 Park Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY, 10154 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Office)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (212)&nbsp;546-4000 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<I>see </I>General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;13, 2012, Bristol-Myers Squibb Company (the &#147;Company&#148;) announced the completion of the acquisition of all outstanding shares of common stock, par value $0.001 per share (the &#147;Shares&#148;), of Inhibitex, Inc., a Delaware
corporation (&#147;Inhibitex&#148;), that were not already owned by the Company and its subsidiaries.&nbsp;The acquisition of the Shares was structured as a two-step transaction, with a cash tender offer by Inta Acquisition Corporation, a Delaware
corporation and a wholly owned subsidiary of the Company (the &#147;Purchaser&#148;), for the Shares at a price of $26.00 per Share, net to the seller in cash, without interest and less any applicable withholding taxes, upon the terms and subject to
the conditions set forth in the Offer to Purchase, dated January&nbsp;13, 2012, and in the related Letter of Transmittal, each as amended and supplemented, filed by the Company and the Purchaser with the Securities and Exchange Commission on
January&nbsp;13, 2012, followed by the merger of Purchaser with and into Inhibitex.&nbsp;The press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exhibits</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Bristol-Myers Squibb Company dated February 13, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: February 13, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRISTOL-MYERS SQUIBB COMPANY</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Demetrios Kydonieos</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Demetrios Kydoneios</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Strategy, Alliances &amp; Transactions</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Bristol-Myers Squibb Company dated February 13, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d300377dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g300377g21h88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bristol-Myers Squibb Completes Acquisition of Inhibitex, Inc. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(NEW YORK, February&nbsp;13, 2012) &#150; Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by
Bristol-Myers Squibb Company (&#147;Bristol-Myers&#148;) for all of the outstanding shares of common stock of Inhibitex, Inc. (NASDAQ: INHX) (&#147;Inhibitex) at a purchase price of $26.00 per share. As of the expiration of the offer, 77,532,611
shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. As of the close of business on February&nbsp;10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery procedures. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Today, Bristol-Myers Squibb acquired all of the remaining outstanding shares of Inhibitex common stock by means of a &#147;short form merger&#148; in
which all such shares were converted into the right to receive $26.00 per share, in cash and without interest, less any applicable withholding taxes. Bristol-Myers Squibb intends to delist and de-register Inhibitex common stock as promptly as
practicable following the effective time of the merger. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>About Bristol-Myers Squibb </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients
prevail over serious diseases. For more information, please visit <U>www.bms.com</U> or follow us on Twitter at <U>http://twitter.com/bmsnews</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Contacts </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bristol-Myers Squibb </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Media: </B>Sonia Choi, 609-252-5132, <U>sonia.choi@bms.com</U>; Jennifer Fron Mauer, 609-252-6579, <U>jennifer.mauer@bms.com</U><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investors: </B>Teri Loxam, 609-252-3368, <U>teri.loxam@bms.com</U>; Timothy Power, 609-252-7509, <U>timothy.power@bms.com</U><B> </B></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g300377g21h88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g300377g21h88.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`&`"R`P$1``(1`0,1`?_$`*8```("`@(#````````
M``````8(!PD#!0($``$*`0`"`P$!`0`````````````$!@,%!P`!`A````<!
M```$!`(&!PD``````0(#!`4&!P@`$1(3(106"3$546$R(S87<8$B8S16-R1D
M-55E5Q@9.1$``@$#`P($!`()!`,``````0(#$00%(1(&`!,Q(A0'05$R%6&A
M@4)28B,S4S14<Q8V%W$D1/_:``P#`0`"$0,1`#\`^S;JN6FK%5I3-JI:)2G_
M`+FJR]^M\$Y!I*0<#-W.(@:_7F3P0`K=_<9`ZYE0$P":+8.4Q\A<)&\-G$XX
M;6\3)W<23#>ZQQN*JS*A9F(^4:TI\G93^J>D7FDES>8^3$V,S0>1&FE0T949
MPJ(I^!D:M==45A^L.E!S*@QE7C%<[DHN@!:JC>5,[NYM,@WUE/6HT8.R6:&T
MZN3`R49)3-?DZ_7S^3"474)[X>\5T@B'RQV[*Y*XN95R,<EUZ>>$21=A]@=M
MRHT#KY@K*S?4@K30J3JJ/A\9:VD1Q,T=GZZ"Y,$GJ(PYC78\BW"-52R-&E-C
MDBNN\"JMCQ"N62E:$3<Z3*6I.F6J.T6<0SQV\$0T'-:%)Y]!2=H5K3<&T7'V
M-%O..9&&:Q[=LBD=`S?R.5YZQESEW;WV*^QWZ1&]A:%.\`28II1,XCWDDE?*
M$D9BU:[M-G4?'K2YQV7'(L<\JX^=9W$&@$T$)A1I2@``?S%X@@`%"NH;JW=@
M^9RC%E)QSI!['R+1N_8O6RA5FSMD[1(X:NFZI!$JJ#A!0IR&`1`Q1`?&0/%)
M%(8I%VR*2&6E*$&E#\C7QZW..2.:-986#1LH*D&H((J"#\B-1TB>N=M3-*ZA
MA.0LVY[O6K:S,Y@ZU\CY>U4S/:`%'9R`P[MZULTZ^?OWSUO,"5H9$K`ODN8`
M]7I`QP?,-P>*^XI+S')Y"WM,3'="VH$DEE[K+N`V*``-NNXMX5TKIUG6<]P9
ML=R^/A&*QEQ>YF2T-S4R10Q=H':2)'))(;RD;1J0/`UZD_E+JVH]55>\R,/6
M+5GUTR71[#D>MYK=4X[ZBHN@UCV3244L^AGDA#3,<L@Y35:O6JQDETS?@4P"
M4*WEO$;[B-W;QW$L5Q97ELEQ;S1D[989/I:C`,K"GF5A5?QZM>&<SL>96EQ+
M!#/:W]E=/;7$$H`>*:/ZEJI*NO[+J2#0_+J2Y;:JE#[74,%=1]P4N=UH]DT"
M)DVE2FG5(;PE6D6$9)-I>YHMS0D3-JN)$@MV:R@*K$`1#R\R`:JAPUW-A)L^
MC0BRAG2)E+J)-[AB"L==S)135@*?G2YFSEG!G(>/NLOKIX'E5@A,>U#0[G\%
M:O@/_%:;EJ3Z+I5"R.F3.A:9:X>ETJOE9FF;).N0:1K`9&0:Q4>FJKY&,==]
M)OD6Z*9`,=594I"@)A`/`V,QM_F+Q,=BXGGOI*[4059J`L:?@`"3\@->B<IE
ML;A+!\GEYH[>PCIN=S114A1^DD@`#Q)TZ-/44Y/44?@(`(#\0_$`$OXAY_'S
M\!'Y?'H_<"*@Z$5\:?G^/2TK=+U]+K*.Y(6I]N1M<EB<ON+2ZN"PR=,>5Z)M
M4+4EHJ/.E*+S;B63DI?][[C1!),$_@8_J`094XO<OQ!N8I-";)+Y+4Q`MW`[
M1O(&8%=M-J:$,3K32G2F_+;5>;)P=H9A?/CGNQ*=O:,:R)$56C;BVY]:A:;?
MC4=!7:7:%-X=I5+TW3:5;I_.+'?(:A3]IJ:U>5^AGD\)ACI69AY:7C962BS-
MFKI50S!-PHD5L(&+YG)YG<(X1?<[OYL7BYH8\I';M,D<FX=W9]2JP!56U%-Y
M%:Z'H#GO/;+V]L;?*Y:WFDQ4URL+R1E/X18$JSJS!F%%;Z`2*>&HJ1=6=?9-
MR1SO-=*7UP\L%*8(P!H!A43,7TO=WMH50+!,*M\T[:1SL[UFJ=X*AUR)$9(*
MK";TD'Q!Q'AF8YCR:/B^.58[YV;>9`0(@@.\O0%M"*4H34@4KT3S+G.$X5Q=
MN59$F6P`3MB.A:4R$;!'4@:@[ZDT"@GJ9,@T%;5<OH>EKU>4I07RL15L9UF;
M?0\C+1D9.-B2,2$@Z@'LE$&<NHQ=%8Q45U`3%3T&'UE,`4F6L%Q63GQBRK/V
M)6C+J&`9E-&H&`:@8$:@5I7X]7^$R9S&(MLLT+VXN8ED".59@KC<M2A9:E2&
MH":5H=0>I(\P_'S\5Q8#QZM*CKSS#QU1UU1UZ\P$/Q_'X>.)'QZ[QTZ1?3.T
M7<!T/+<P8WA5VWS5J?G$7JNB-8.T42B0-.J4]('CJ^B:;O<U&)3=FFUDC&19
M-B>@J8E,JLF`CZ7O%\(BN>.IRC-7\&.Q,URT$)=)96DD4`N0L2MM1*BK,:UJ
M`#3K.\QSR6TY*_%<#C;C)Y>&U$\P22&)8T;1!NE9=SO444:4(J1\&`YZV%3=
M\DK.FNJ);,ODII>QQTSGEY;D;VRH3=6LTQ5I>&FTT0^6,Z0?0QS%.B)T5$SE
M,F<Y!`PKW(L../Y>7%BXBNHTV%9HC6.17175E/C0AA4'4&H-#TS<9SHY'A8L
ML;>:UD<NK0RBDD;1NT;*PT'BM01H001U-/J#]/X^*7<*T^/5]4=1%K>T5+&4
MJ`O;&%O?DTC2ZGE,#](5";MQV=EN2SI&*>V!.%;.30-9;F:F%U(K@5NW`0]0
M_$/%MB,)=YPW`LGA4VUK)<-W)%CJD5"P3<1O<U\J+J?AU1YS/V.!%LUZLS>J
MNX[=.W&TE'EKM9]H\B"AJYT'0%S_`-+U[H.Q;_7(2GVVHON?-A?8U9$[>6&2
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M`K]MR(]I7?5U755&IZ4+=)"XC:GYWKFQ-T3T'T4U3."KV.K2JB2DLUB64U-W
M^886A]F0-!=E0<N#G:>ZFV1;.Q9&,0'+`1XST:A.S47'G[QV.HHI+*L:&,35
M()"C=3<67=MJA<DER0R#-(TZ@V](^P-Z/]056>5^X8`-VTL=OTA7*D@-O7G%
MR"JL'SR+Q`+/'-*\S82=ALVB1NVPZPLB%J\=3(^$61EXQJ[:>G\N9UMN:'?(
M@(D*Y)[IA3KI<;ZMT1[WTK.Q8*L9MFU\YD+)M8@_6TI[BG]D@=/ME)DELD:1
M+#UJH@4N\@NEH/X:Q*CU4$4VK"#$XK]0)JZ?$SG17.()?S&06;N6]TN[2JD<
MMHMHL--;SJZ<44$8AV[:E9H/`<I-!\D#?*)I![*90*'A+YNN*7.$8@AHF@B+
MT+$=TKYM6`-3H6\1NW:FG3[[>ME6XZ/NP(D%Q*(ZA5/:W^71&84KN"Z_2!H.
MD-VFO6>U?>3I4#3+W)YE9)'[<EQ2C;S#PE>L<E`G#=&IU'#2&M;"4@'AU4BF
M2_VA!0"^KS#R,`"#[A+BVM?9BYN;RW6YMUY)%6-F=%<>E.A9"K#YZ,/QZSCD
M%I=7OOM;6]A<O:7;<7FI*B)(R'U0U"R!EKK35?CIU7]4]=W3!:WM?/N7:`RI
M>IT3[H>+Y5KG14)6HRS2_1I.EI-XXDKG>(^YC8T(.^P:$0FF]9Q:R$>4H)MT
MDD4_5ZM'O,1Q_D%Q9<DRMN\^)FXI=3V]DSLBV?H5&V*)H]I:%MQ*,X+G5BQ-
M*9G99CD7&K2^XUA[KL9J'EMK;W-\L:R->^N=P991+O"RIL&Y8RJ4.P`>)L=N
M]FZNR+J+*.;:YTO+:*O9.+>I+K$3NK57.HEG(;+6YZ$:YO;+J^JM9A2*1<$O
M9$&IVZ94FWL-_69,YU#^,TL+/B6:XK>\FNL8MLL6;L8F2WDE)%O(CF9(@[L=
MS",L&))J:5``ZU7(W?,\'RNTXO:99[EI,%?2))<QPJIN4<"&25HT71"RJ1H*
M#4$L>JS^@-/U/1>+NG,OW/6>CJCT+D$/S$XV#`M:B\R<LW$Z^W"OQ3K6\ROE
M8IT>TM6/WE[))JM&:``I&/8UL7WS(&.FMJO&<7B<=SS%Y?`VN-FXW=M?^GNK
M<S`A5M7;TT\+N62XB`H7)&]78T!H1C_+,KF<E[?9;#\COLI#R:S7'FYM+E82
M&=KJ,-<6\J1J'MI"P*H`>VR*-S*=;*<_G>@^@M.[7I;3J'3LHAN.96#R3,SQ
M<7F2LY:+<GGC>[R6O[6M+4)PSM$=-/WR2+6+9-XF."-0.;R%8_O%RW)6_'^.
M8G"9!L5:WDV:$D\VXRA4C[O;6WM@L@[;*`2TC;W+E?U1M.NXZ7D_(\KG;%,S
M>64&#V00;5AW22B(RM<W1:(]Q'-`L:B-=@/ZWFZ7+E/I^V;SU#RSU#=*=)2M
MSG/M6;-.V.I9W%E>25JFZ?TG$5]\:C0CY\U266M[F!%U'M#N2$#YHB?N^D`,
M++RSBUGQ_BF7XM8SHME'RRV1))6HL:O92,.ZRAJ=O=M<@$^4FG2GPWF%]R/F
MN'Y=D+>1[^3AMTSQ0IYY&COXT/:1B*F0I55)`J:`],_U=?XCJ*D<WUNZ8-LN
M<5>5[GQ"D6&J[W2XNIN;=`V:J:(UE1BF<79+(1[%_)NCH*J&.D=-8?[(?`#>
M%+C..GXI>Y&XLLA97-TF#N)4DM)6D$;))#3<2B%6J*@:Z>/RZ<>99*WYKCL5
M:9#&7]K9/R&UBDBO85B,B20W`;:H=ZK0D$U!!\/GU7!M_/71M,X4[!SCH9FY
M?Y3PAE>GYMRI:)3WEG>M15_>0Z]<TM\4YA14=97DCLE59'+Z@(K(/R>8*(B/
MC4>/\DXW?^X.'R?&V"Y?/7,4U_&I%+=HE<-""-0)YQWW!I4(GP-.LOS_`!;E
M%CP+,8ODXWX7CUO)!CW:M9Q-+&5F(("DV]N1`A%0I=UU*GIODN@]3Y9F\D97
M[2[C)8;OG`T0YYW@&4?2V9ZMTU2:+5C*YK"2@5%62DY>\Q,@S6KA))9X4'OS
M*1TUR>GT(W^V\9RNTNY<=;1#/8[/MZQBSD/92R/29AOH%B8,LI7;Y=K5!.KJ
M>49?AT]E%DKJ9N/Y/C:^B4!`4OXXH_X"GMZM(I!BWD^8D4(%0!(ZYW/?[AT!
MA=1V#8YS=.<R9)D^>%HU.S-G4K-L]GSUKI.@;)TE9)>D?3T)C#.3D`BXJ.;`
MT6=1K<2M4GD@<3DLOL_`\;9X[.WUG:)@LF;B>8RO,72VCE,$5O9HLF]KF@[C
MN:A2R[RJ"G54,S[BY._R'';*_OI.0XP6T$(ACA6-[F2+OS7%_(T11+8'^%&B
MT+*/('<Z3C79KM/2^NNI,S6ZU+1T.><NYPT&'K->HF?DS2:O=[H-HE+!7IV8
ML%;D+.3+7%FC3'44!<DL=H8GFN040*:CN8>#XKA^)R0Q'?;)7=[$TCRR]Y88
M9D561$=4[XC8`:%`U?+YM&&UN.?Y?F^9Q)S?IAB[*QF5$AA].TTT#,RLSH7[
M'<4DFN\J1J-M"4_;KV789S5+ABO3N@;3#]+4++(V0TS$=8B**_J%B?'LX-%-
M]P&_4>"@FLCFTVJL+`\2I\Q^7F.@4I_414R@GN3A</;XF#.<7M[%^+W%TPAN
MH&E$B#MU%I=Q2LU)D^K>*%]32E`#O:[.YR;-7&`Y;=WZ<JM[4&:UN5B,;GN?
MW=G+$JUA8$(8SN"&E&.IZ.NM^.U-PU%QTER#MS?&>X<2C&E->S$3(,YFJ7&)
M%DA:(G*-WIX*."_EDM'R:2K1PLD*J+=R104EB%1%(#AO-5P.+_VQS&Q-]P2_
M<R!6!62)J[&GM9/VE*T8`T)&VJDFMES3A#<@S!Y3P?("QY_CT$;%6#1RK0.M
MO=1_`,I\I(I0@E6VKM4GG/N;;ON&ZISSDC2TV'F.)5P+5-5W5UF!:ZM:;=HN
M=ZLIC)*U1K/<(2VLXFB-Y9JI+*F0;*NU`5*U.L)4S'.X<DX%@?;C%9+,F),I
M+]Q@@M1/OV1PSV_J1)*B,A:0IY`"P44WA?ATC\7]P^1^Z&9QF"2:7$0_;I[F
M[:#M]R66&?TX2)Y%D"Q;J2':&.NPL=#UH.4>F^H)C3>'ZY<]VLMVAM4Z>^X-
MFNEM)F!J:2UNC<':V!O072CIA"MEH-O&IM43BQCOE&8JI^X)!$3`)7+.*<6B
MQF?N[.PC@FL\;B98-KR4C-W0RBA8AR36C-5@*BOAT-Q#EW+I,QQVRO<C+<6U
M]E,O#.'2.LJVB@1&H4%0*UVI1:@?C7;,>I^ID\XKLX[W"3DI1G]YA3D^?>_1
MU'9FLV+!=8^%;U8R;2$!&!20;1Y_6JR`CE7YA0IE?P\A3Q3BK9*2!;!5C;A'
MKU'<E.RY[+/W-6\VI'E:H%/#HA.9<Q7%17#Y!FD'/ACG/;B'<M>\J"/1?+0`
MBJZG<17PZ"YN=TS+Z1]Y#H3*=AM>87+!NL[1H$'%LFU5D*-<GL-E^1OU8&]P
MT_79-],L)Q@0[!--L\9&2.Y*H014`H^#H8,7E+SA7'<O9Q75ED,0L+DEUDC#
MW-RH>)E90K(2')96#4H=.A)I,OC+3G')<-D)[2^Q^:>9%41M%(5A@JDJ.C%@
MXJE`RD$U\>B6!D="NNG?=4VNG:I=,!O5=PGDC;V"U73K#F+3LZ/)<A=VL+<X
M^W5R="6K4>_0.@JU(=J91%0_K.)BD$HLT>/L<5Q/"7EK!D+&7(Y"V._>#VS?
MI&6C9&7:Y!W!O-2@T&O4EG+E,AF.9<@L;NXQF1BQF,NQLV%>YZ"24)()%8M&
M""I4;:AB:UZZW_M@Z*_[:0O_`,D?_-'_`(0^_P!8O^8?M_P+_N?[?][X*_Z>
MXU_EG_F'VWQ_^?\`9_U?WORZA_[JY5_BP_\`#?N?TG^X_J?Z'[OY]6J=<1PU
M6FS>BMJR]M<"\&E1VC5J+BBS+YTUK]W@Y>KVQM%"BL#EQ`K$79O#^D1*P>%7
M4,";$/+'.(OZR_CQS2+#<#>T3LVP`LC!XRW@-WB/WEVC5^MKYO&;''2Y1(6G
MMB$6>-5W,0LBM'*!3QC(*D_!&W$TCZ5+.+]7]"8N]1>/<XL4U=[DK>+K];Z1
M6Z>TDZ8A7[)5(#*:&QF5'$A()LH2P>Z=X_2C8Q10H)`X5$!62:,I97&/E7%H
M+B*&WC"1]J)G(EW)(\\I735EH%4NP\:#P9.P]];Y6-LR_II;BXF,DHEF2,-#
MLDB2VA5]3M5ZEG"(2`M32J]'%+RZN&E1N$T8).:7I$+I%4AM+^11<2&<9=<Y
M'/)APTF9YK\ZT8VR(BHYW'Q`MW*S5ZY73.W.HW;*"!.9L%LL4^>OBJ"=X)&A
MJ0)IT$R@HAH3&Q(>2JAE`H0&8*!L#D);S,)QK'"1_31W$8GH"8+>4P-1G&X"
M1%#)&`Q#$@@E5)-OD3%1\'&1T-$M$6$7$L&D9&L6Y?0@SCV")&S-JB3S'TI-
MVZ92%_4'C())7GE::4EI';<2?B2:D_I/6YP016T*V\*A844*H'@%&@'Z!3I4
MM1X<Y_U78&O0,G&7FH;<UKWTD&H9?J.A9M:G%7]KV?R!XYJ5BC6CJ-]OX"0Z
M(B(^0B/F4H@WXGG7(,-AFX]"T$V#:3N=B>&*:/N:><!T)#:#6OATE9OVZXSG
M,VO)9TN(<^L?;[]O<302&.A&PF-P"NITIT.'^W9R;]`5S-&N?3,76:WIZ&UI
M*0^AZ%&V.=U]JNFZ9Z7<[>TLR=GNMQ8O$P60>2CMT=`_Q3](>0!-_P!B\N-_
M)E)+E6NI;4VM#'&46V(H8(X]FR.,C0JBK4=#'VNX7]MBQ,=LZ6<-X+ORS2AW
MN1J)Y9-V^20'4,[-0^'1IK?%^";E=_YA:5!6F;M)<VLV1%=-]$O<.Q#/+FV.
MUM5=_)8>P,H@R,^`D5<JB@*ZCA!%7U^XBF8H.(YGR#`V7V[&2QI:FZ2XIVHR
M>['_`"WW,I:J:T%:4)%*$]6&;X'QSD5]]QR\<TEUZ1[;2:5089*AU*JP7S_K
M&E:T/B!T&//MZ<R3%6U&J6JO7:\DV"L5.D7*RWO4=#M]Y&FT*83L5'K$#=9V
MQ/;#7(>JV$@/VJ;-=(QG?[U4RA_CXL(_<7E,%[:7MG)#;FRFDEC2*"*.+N2J
M4E=HU4*[.AVL6!&WRB@ZKG]KN(3V-Y87D5Q<+?1112R2SS23=N%@T2)*[ED6
M-U#`*15M37KG-_;YYPG5WSQ5IJ,;)V.H,*%H\Q!;;K,'-;)4XP')&<7L<O'6
MY"0T=1)N]70!W(J*O2M%C-BK`W\D@^;?W$Y-;T4&U:..=IH5>W@=;>1J5:W4
MQD0Z@':H"[@&INUZ]N/;#BER6)6\226!89V2ZN$:YC6M%N660&>@)&YR6VG;
M7;IT?USC_!*?J=)V&I5)_5[CF^;M\>HZ-?M=JB:C7<P;E2$E(CZ*SF$J@6!,
MZ03='3,S,*CQ(BYA%4H&"MN>8<@O<3<86[G[ME=77J9=Z(SO/J.XTA&\M0E1
MYM%)%.K6UX1QRRS,&=LX#%?VMH+6+8[K&D%0>TL0.P)4!CIJVIUZ*=HYUS/?
M5<_6TAO:W1\PMS*^TOZ;O]VI)(JXQOE^5V%4E0GH4DE(Q1?65J=R"WL%65`@
M%!4_J%PW(LIQX7`QC1A;J$Q2!XHY*QG4KYU:@)I6E*T&N@Z+Y!Q;$\F-L<LL
MK-:3B:+9+)%ME6M'_ALM2!4"M:5-*5/6QW3"<XZ/S:;R+6HR6G,_L@M0L,'%
M6>RU3\\;-5?>)&2C^K2D1(O(E98`,LT.J*"PE*)RF](>(\!G\GQG)QYG$.D>
M1BKL9D1]K']8!U9:T\#2HZFY%QW%\IQ,F$S2R/CI""RH[QE@IJ`60JQ%=2*T
M/QZ5JZ<QN)C2N.\BA<]!QS-S%(N=G^MKA:S7"R(Z'3(Q_5\;SJOJV26E[N=M
M#&L+F6=OEQ,W(VC6;,B@@)B%:['E`@Q>9R\UP1RC**+;MHFQ##(0]S,^P+%5
MM@C51YMSNY'QZ2\CQ!KC+X+"6]K7B.(<W7=D<2/WHE9+6%-[-+12YD8D;:(B
M5^'4Q:%QSB.C:1)ZV^87:IW^QUYC4;S8<PTV_P"7KZ/58OW`C*_H*-&L,(WM
M;..36.DW5<E%T@@H9(BI4Q]/BFQW-,[C<8N'0PS8Z.0R1)-#%-V)&IN>'N*V
MPM0%@#M)%2I.O5_E."<?RV5;,RK<0Y&6-8Y7@GF@[T:UVI,(G42`5(!8;@#0
M&E!UKH?B+G2OS&M3<13YAHOM^;M,CTB.&[W-S7YG.XV"6K,'66E;=SB\'",Z
MU`.%6L:9F@@HR164!(Q?6;S]N.;<CN8+6VGF5H[&Y:XA/;3<LS.'=RP4,Q=P
M&?<2"0--.H[?V^XO:7%[=00NKY"T%M..Y(5:$)L1%4L0HC3RH5`*@FGCUOL=
MY+QS$+6]OM1:7*:N[JEQ&:M;;HVAW;2[#!YQ!/#2,70Z[*7><FG,)5V\D<7)
MFZ!BBNN!3JF.)"^F/.<OS6>M%Q]ZT*6(G:8QPQ1PHTSBC2N(U4-(1I7X#0`5
M/4^`X/@..7C9*P6>3(-`L`DGFDGD6%#584:5F*Q@ZT'B=23T$Z1P9@.GZ3>=
M<E2ZG5[_`*7#0%<OT[F6U:EF(6ZOUN+4AHR&G8ZCVF$C9!J2,/[1C*)&7$H`
M`*%\'XGW!Y'B<;!B(?2RX^U=WA2>V@G[;NVYF0R(Q!KKXT^8ZK\K[:\8S&6N
M<W/ZR')7:(DSP7,\'<2--BJXBD4,`NAJ/T]<Y/A+F9M!9.QJ6>S&>+X#!S4#
ME4ACMUMF:7"'K4Z(O+)3RV>MV&$DIF(M[TOO/D9)TJ1R\.+@YRK&,KX^(>>\
MH:>[DN[A;E<@ZM.MQ&DR,Z:))L=6"M&-%*`$+Y0-H`Z]E]M^)+:V4-E;26OV
MU'6W-M+)#(J/4O'O1U+K(22P<FK$DD$D])]R'P<A.8.UIW4N57"@7W.^GMXV
M;*9ZOZB,'<JXPU:VS4TRD("^9%>%95BL^K<P#"6;+.2@LJF;S!4H$4%UYG[@
M/;\A:]XK>0W-A<XNVMYU:"L;F"-4(>*>(+4.-\;*-`:U!J.D;A/MLEWQL6',
M+*XMLC:Y:ZN;=UN`LJ+.^ZJ2V\S,`RG;(K-K34$4/3/-?MN<G1]?9U2+J%VB
M:S';`UWV-@HS8M;;,([8V7MF;:`T)]9F5)/I+I`M[@G$#+^:ABB<1,*B_N3R
MV2Y:[GGB>[>R:T+F"#<;9O&+1*;:&F@!`T'3@GM3PJ.W6SB@G6S2_%XJ"XGV
MBY%*2T[A.X4KXTKKX]8W7VV.3GMGN]@=5*ZN(W3+NQTC2\]<ZWI[O+-$O$8\
M1D&%ANV>N[6O6[&NV?-TU00<HG:&%(A3I&(0A0E3W,Y=':P6T<T*RVL!AAF%
MO")X8F!#)'*$#J""1H014T())/R_M/PN6\N+J6&=HKNX6>>$W,YMYI5.X22P
MERCD&AH01H-*`==NY?;GY:O-[TN_3-;O;=_M8Q)-GK\%KVI05(UAI!$!**B[
MY3HNUM8*8A6C</9*S]I-J+<QD13%(YB#'8^Y'*L?C[?'0R0&.RW&V=H(7E@+
MUW&&1D+(Q)))J37S5J`>ON_]J^&Y#*764FBN%FO]OJ42YGCBN`GTB:-)`K*H
MT"T`IY0*:=-=_+'.O\B4_P#@?^6/\.Q/^G'^0_\`"_P?_P!._P`)_=^%/[GD
KO\F;^?WOK;^=_5\?YG[_`(_CTZ?9\3_C0_V_I_H3^W_H^'\K]SZ?PZ__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
